Scimplify Raises $25M to Scale AI-Guided Chemical Manufacturing
Scimplify has raised $25 million in an all-equity strategic round led by Hitachi Ventures. The Bengaluru-based company disclosed the financing on Oct. 14, 2026, at a post-money valuation of $250 million — its value after the new money is counted — according to a person familiar with the transaction, up from $150 million after its March 2025 round. TechCrunch
Henkel and Teknor Apex joined as new investors. Existing backers Accel India, Bertelsmann India Investments, Omnivore and 3one4 Capital also participated. The company previously raised $40 million in a Series B in March 2025. Total equity funding now stands at $80 million.
Scimplify was founded in 2023 and is based in Bengaluru. Co-founder Sachin Santhosh leads a model built around centralized process development and distributed production. The company develops chemical manufacturing processes at research facilities in Bengaluru and Hyderabad, then transfers them to partner factories for commercial production.
That network now spans more than 500 manufacturing facilities under Scimplify oversight. About 90% of manufacturing currently takes place in India. The company plans to expand its production network to the U.S. and Japan over the next year.
At the center is Scinode, Scimplify's proprietary AI platform. The company describes it as AI that powers every node from science to manufacturing. Scimplify In practical terms, it links the workflow from route scouting, or finding a workable way to make a molecule, through optimization and scale-up to oversight on the factory floor, rather than acting as a single model for molecule design.
Commercial traction has moved fast. Scimplify has reached an annualized revenue run rate of about $200 million, or its current sales pace projected over a year, tripling from a year earlier. It serves more than 1,000 customers and has delivered products to more than 40 countries.
The geographic mix has shifted with it. Customers outside India collectively contribute more than half of revenue, compared with less than 5% about 18 months ago. The U.S. market accounts for roughly 30% of business. U.S. annualized revenue run rate rose to about $60 million from $10 million a year ago.
The company lists its global presence as USA, UAE, India, Japan and Indonesia, and states its in-house labs are backed by 600+ scientists and advisors. It states it serves Life Sciences, Crop Sciences, Critical metals, Advanced Materials and Industrial Chemicals industries.
The broader context here is procurement risk in specialty chemicals and critical materials. Western buyers have spent three years looking for non-China sources of qualified capacity that can move from lab validation to repeat commercial batches without multi-year plant builds. An intermediary that holds process IP, qualifies distributed capacity and manages quality across sites addresses that bottleneck directly. The math is straightforward. Scale is the test.
To read the investor mix as a customer signal, Hitachi Ventures, Henkel and Teknor Apex offer strategic capital, not just balance-sheet capital. In specialty chemicals, qualification cycles are long and failure modes are operational. Having industrial strategics on the cap table can shorten trust cycles with new buyers and toll partners, and can open pilot demand for higher-specification molecules and materials.
In my view, the next 12 months will be defined less by revenue multiples than by execution in two new manufacturing geographies. Operating a 500-site network concentrated in India is one problem. Replicating process transfer, quality control and on-time delivery in the U.S. and Japan, with different cost structures, regulatory regimes and labor markets, is a different one. Rapid international revenue growth suggests demand is already pulling it in that direction, which reduces the usual greenfield risk.
Looking ahead, success would bring practical gains rather than abstract ones. More second-source capacity for agrochemical intermediates, pharma building blocks, advanced materials and critical metals. Shorter lead times for buyers managing tariff and export-control exposure. More process data feeding back into Scinode with each tech transfer. If sustained, that feedback loop is what would make the platform defensible over the long arc.
